NUVARING VAGINAL RING CONTRACEPTIVES vs. YAZ BIRTH CONTROL PILLS
During October 2011, the FDA released the results of an FDA funded study that evaluated NUVARING VAGINAL RINGS and YAZ, as well as other DROSPIRENONE (DRSP) containing birth control pills. Both are combine hormones to prevent pregnancy. NUVARING VAGINAL RINGS are literally inserted into the vagina and left for a fixed period of time to release hormones. As a result, they have been marketed as a relatively maintenance free form of birth control as depicted in the video below. Such marketing failed to underscore serious risks. Similarly, marketing of YAZ as a lifestyle drug failed to underscore safety concerns prompting an FDA WARNING LETTER.
However, like YASMIN, YAZ, BEYAZ, SAFYRAL and the generics OCELLA, GIANVI, the NUVARING was a “new” contraceptive introduced with little independent study or scientific evidence evaluating risks to users. Both the pills and vaginal rings are not the subject of thousands of lawsuits from girls and women claiming personal injuries.
FDA’s own study of October 2011, found that both increased the risk of blood clots, which can lead to death, heart attacks, strokes, pulmonary emboli, deep vein thrombosis, and a lifetime of health complications. While they are both forms of contraception, they both appear to present high risks of blood clots and may not be the 1st recommended choice of any ‘first time’ user of birth control. With regard to NUVARING VAGINAL RINGS FDA’s study reported a 48% higher risk of blood clots in women using a vaginal ring compared with those using contraceptives containing levonorgestrel.
A recent study, published in the BRITISH MEDICAL JOURNAL, (BMJ), entitled “Venous Thrombosis in Users of Non-Hormonal Contraception: Follow Up Study, Denmark 2001-10” compared YAZ PILL SIDE EFFECTS and NUVARING VAGINAL RINGS and found that vaginal rings increased the risk of blood clots, or venous thrombosis, 6.5 times compared with non-use of a hormonal contraceptive. This risk was comparable to that of a DROSPIRENONE (DRSP) containing birth control.
On April 10, 2012, FDA announced that the DROSPIRENONE (DRSP) family of contraceptives would carry a stronger warning of the potential for higher risk of blood clots. This action was a follow up to hearings during December 2011 evaluating both methods of contraception. Sadly, at the time FDA concluded it’s own study by noting that increased risks were found for vaginal rings and that concern merited additional studies.
FREE NUVARING VAGINAL RING AND YAZ BLOOD CLOT CASE EVALUATIONS ARE AVAILABLE FROM THE SPONSOR OF THIS SITE THROUGH USE OF THE CONTACT FORM BELOW. ADDITIONAL INFORMATION ON THE NUVARING VAGINAL RING LAWSUITS IS AVAILABLE HERE.